Design Therapeutics, Inc. (DSGN)

Design Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	0.23
Revenue Growth (YoY)	-	-	-	-	-72.90%
Cost of Revenue	44.35	57.06	48.61	24.78	6.06
Gross Profit	-44.35	-57.06	-48.61	-24.78	-5.83
Selling, General & Admin	18.03	21.13	18.98	11.05	2.5
Operating Expenses	18.03	21.13	18.98	11.05	2.5
Operating Income	-62.38	-78.19	-67.59	-35.83	-8.33
Interest & Investment Income	12.8	11.33	-	-	-
Other Non Operating Income (Expenses)	-	-	2.89	0.22	-0.02
EBT Excluding Unusual Items	-49.59	-66.86	-64.7	-35.61	-8.35
Gain (Loss) on Sale of Investments	-	-	1.4	0.08	0.07
Pretax Income	-49.59	-66.86	-63.31	-35.53	-8.28
Net Income	-49.59	-66.86	-63.31	-35.53	-8.28
Net Income to Common	-49.59	-66.86	-63.31	-35.53	-8.28
Shares Outstanding (Basic)	57	56	56	46	16
Shares Outstanding (Diluted)	57	56	56	46	16
Shares Change (YoY)	1.08%	0.50%	21.27%	190.80%	2.08%
EPS (Basic)	-0.88	-1.19	-1.14	-0.77	-0.52
EPS (Diluted)	-0.88	-1.19	-1.14	-0.77	-0.52
Free Cash Flow	-43.45	-58.82	-52.24	-30.92	-8.75
Free Cash Flow Per Share	-0.77	-1.05	-0.94	-0.67	-0.55
Operating Margin	-	-	-	-	-3685.84%
Profit Margin	-	-	-	-	-3663.72%
Free Cash Flow Margin	-	-	-	-	-3869.47%
EBITDA	-61.79	-77.65	-67.19	-35.7	-8.33
D&A For EBITDA	0.6	0.54	0.41	0.13	0.01
EBIT	-62.38	-78.19	-67.59	-35.83	-8.33

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q